Release Summary

FDA Accepts Two sBLAs for Merck’s KEYTRUDA for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment Settings

Merck